Global patterns of opioid use and dependence:harms to populations, interventions, and future action by Degenhardt, Louisa et al.
                          Degenhardt, L., Grebely, J., Stone, J., Hickman, M., Vickerman, P.,
Marshall, B. D. L., Bruneau, J., Altice, F. L., Henderson, G., Rahimi-
Movaghar, A., & Larney, S. (2019). Global patterns of opioid use and
dependence: harms to populations, interventions, and future action.





Link to published version (if available):
10.1016/S0140-6736(19)32229-9
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Elsevier at https://doi.org/10.1016/S0140-6736(19)32229-9. Please refer to any applicable terms of use of
the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the





Global patterns of opioid use and dependence: Population harms, 1 
interventions, and future action 2 
 3 
Professor Louisa Degenhardt1, PhD, Professor Jason Grebely2, PhD, Jack Stone3, PhD, 4 
Professor Matthew Hickman3, PhD, Professor Peter Vickerman3, PhD, Brandon D.L. 5 
Marshall4, PhD, Professor Julie Bruneau5,6, MD, Professor Frederick L. Altice7, MD, 6 
Professor Graeme Henderson8, PhD, Professor Afarin Rahimi-Movaghar9, PhD, Sarah 7 
Larney1, PhD 8 
 9 
1. National Drug and Alcohol Research Centre (NDARC), UNSW Sydney, Sydney, Australia 10 
2. Kirby Institute, UNSW Sydney, Sydney, Australia 11 
3. Population Health Sciences, University of Bristol, Bristol, UK 12 
4. School of Public Health, Brown University, Providence, United States  13 
5. Research Center, Centre Hospitalier de l’Université de Montréal (CRCHUM), 900 rue 14 
Saint-Denis, Montréal, Canada 15 
6. Department of Family and Emergency Medicine, Faculty of Medicine, Université de 16 
Montréal, C.P. 6128, Succursale Centre-Ville, Montréal, Canada 17 
7. School of Medicine, Yale University, New Haven, United States 18 
8. Bristol Neuroscience, University of Bristol, Bristol, UK 19 
9. Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, 20 
Tehran, Iran 21 
 22 
 23 
Words: 5100  24 
 25 
 26 
Corresponding author: Professor Louisa Degenhardt 27 
National Drug and Alcohol Research Centre 28 
UNSW Sydney 29 
Sydney NSW 2052 Australia 30 
Email: l.degenhardt@unsw.edu.au 31 
Phone: +61 2 9385 0333 32 






This paper summarises evidence for medicinal uses of opioids; harms related to the extra-36 
medical use and dependence upon these drugs, and for a wide range of interventions to 37 
address harms related to extra-medical opioid use. GBD2017 estimates suggested 40.5 million 38 
people were dependent upon opioids (95%UI 34.3-47.9 million) and 109,500 people died 39 
from opioid overdose (10.5,800-113,600). OAT can be highly effective in reducing illicit opioid 40 
use and improving multiple health and social outcomes, including reduced overall mortality 41 
and key causes of death including overdose, suicide, and other injuries. Mathematical 42 
modelling in Kentucky, Kyiv and Tehran suggests scaling-up and retaining people in OAT, 43 
including in-prison OAT, could avert a median of 7.7%, 14.5% and 25.9% deaths over 20 years 44 
(compared to scenarios without OAT), with more impact in Tehran and Kyiv due to reductions 45 
in HIV-mortality. Other interventions have varying levels of evidence for effectiveness and 46 
patient acceptability, and typically impact on a narrower set of outcomes. Other effective 47 
interventions focus on preventing opioid-related harms. Despite strong evidence for the 48 
effectiveness of a range of interventions to improve the health and well-being of people who 49 
are dependent on opioids, coverage is low even in high income countries. Treatment quality 50 
may be less than desirable, and considerable human, social, and economic harms arise from 51 
the criminalisation of illicit opioid use and dependence. Alternative policy frameworks are 52 
recommended that adopt a human rights and public health-based approach, do not make 53 




Key messages  55 
1. Opioids are essential medicines for the treatment of acute and cancer pain and opioid 56 
dependence, though access is often inadequate.  57 
2.  extra-medical opioid use, dependence and harms are increasing globally driven by ready 58 
supplies of illicit opioids and in some countries over-prescribing of opioids for non-cancer 59 
pain.  60 
3. Adverse health outcomes of opioid use and injection include overdose, suicide, accidental 61 
injuries and infectious diseases (e.g. HIV and HCV). Overdose risk is elevated after periods 62 
of abstinence and in the context of polydrug use 63 
4. Many people with dependent opioid use experience long-term cycles of use, treatment, 64 
abstinence, and relapse; criminalisation of use means many face arrest and incarceration, 65 
increasing harm. 66 
5. Opioid agonist treatment (OAT) is the most effective treatment for opioid dependence, 67 
with impacts across many health and social outcomes. Modelling suggests that compared 68 
to a scenario with no OAT, scaling-up OAT to 40% coverage in the community, increasing 69 
duration of OAT to two years and providing OAT in prisons would avert between 7.7-70 
25.9% of all deaths, 39.2-57.0% of overdose deaths and 34.9-56.2% of HIV-related deaths 71 
over 20 years. 72 
6. Other interventions have varying levels of evidence for effectiveness; few show the wide-73 
ranging benefits across multiple health outcomes that OAT does.  74 
7. coverage of interventions is typically low and treatment quality suboptimal. Policy 75 
changes that prioritise prevention of opioid-related harms and scale-up evidence-based 76 
interventions are urgently needed.  77 
8. The criminalisation of illicit opioid use and dependence produces considerable avoidable 78 
human, social, and economic harms. Policy frameworks need to adopt a human rights and 79 
public health-based approach, addressing the criminalisation of a chronic disease, and 80 
seeking to reduce drug related harm at the population level. 81 




Background  83 
Opioids are among the world's oldest known psychoactive drugs, with the use of derivatives 84 
from the opium poppy recorded for thousands of years. A wide range of opioids are used for 85 
medicinal and recreational purposes, and include natural (i.e., plant-based), semi-synthetic, 86 
and synthetic opioids (see webappendix A). Opioids are WHO-listed essential medicines for 87 
acute and cancer pain, palliative care, and treatment of opioid dependence1 (throughout this 88 
review we use the term dependence to be consistent with WHO’s International Classification 89 
of Diseases [ICD]; see Panel A for terminology). Use of opioids for extra-medical purposes is 90 
illegal in most countries, with punishments ranging from fines to incarceration.  91 
We use extra-medical use to refer to use of illicit opioids, and/or pharmaceutical opioid use 92 
either without a prescription or not as directed by a doctor, while allowing that the user may 93 
have medically driven reasons for using the opioid. Extra-medical opioid use occurs 94 
worldwide. Many people use opioids initially because they enjoy their effects (see Panel B for 95 
some perspectives from people who use drugs), without necessarily choosing opioid 96 
dependence and long-term health and social consequences. The complex intersection of illicit 97 
opioid use with increased rates of prescribing for medical purposes in many high-income 98 
countries, most notably the United States (US), has brought increasing attention to extra-99 
medical opioid use and opioid-related harms.  100 
Opioid dependence (as defined in ICD) involves a cluster of symptoms including impaired 101 
control over use, prominence of use of a substance in a person’s life and physiological 102 
symptoms including tolerance and withdrawal2. In North America, the term opioid use 103 
disorder (OUD) (from the American Psychiatric Association’s DSM-5) is often used in 104 
preference to opioid dependence.  105 
Panel A – terminology 106 
This paper summarises evidence for medicinal uses of opioids, and harms related to the extra-107 
medical use of and dependence upon these drugs. We also summarise the evidence for a wide 108 
range of interventions to address harms related to extra-medical opioid use. Finally, we use 109 
mathematical modelling to estimate harms and explore the overall health benefits of opioid 110 




harms (overdose, HIV, HCV, suicide, accidental injuries) and responses. The approaches used 112 
in reviewing literature for each of the sections are detailed in the appendix.  113 
Medicinal uses of opioids  114 
WHO lists opioids as essential medicines for acute and cancer pain, palliative care, and opioid 115 
dependence1 (see webappendix B including Panel B1 for a discussion of evidence for 116 
medicinal use of opioids). In some countries, particularly the United States (US) and Canada, 117 
there have been considerable increases in the prescribing of opioids for a wide range of 118 
chronic non-cancer pain (CNCP) conditions over the past two decades. Evidence for the long-119 
term use of opioids for CNCP is limited,3 and subject to considerable controversy.  120 
International Narcotics Control Board (INCB) data on country-level use of pharmaceutical 121 
opioids (Figure 1; appendix C details how data are collected), shows opioid analgesic use is 122 
low in Africa, Asia, Central America, the Caribbean, South America, eastern and south-eastern 123 
Europe4.  124 
In countries with the highest opioid consumption (Figure 1), most use is for CNCP. The US far 125 
exceeds other nations, consuming 68% of the world’s prescribed opioid analgesics between 126 
2011-20134.  127 
Figure 1 – opioid analgesic consumption 128 
Epidemiology of extra-medical opioid use and dependence  129 
There are varied trends across countries in patterns and harms of extra-medical opioid use 130 
and dependence. Illicitly produced heroin has traditionally been the dominant opioid used 131 
extra-medically. The notable exceptions have been source countries and their close 132 
neighbours such as Afghanistan and Iran, where opium has been the most common and 133 
heroin use and injecting are now increasing5.  134 
In many parts of South America, the Middle East and Africa opioids like tramadol are 135 
prescribed for pain. There are also reports of significant extra-medical use of tramadol, 136 
accompanied by dependence, overdose, and death6; there is some suggestion that much of 137 
this is illicitly produced tramadol6. Similarly, problems related to extra-medical use of over-138 




is evidence that substantial amounts of opioids, including fentanyl, are illicitly manufactured 140 
in Mexico8, China and India9.  141 
In high-income countries, increased prescribing of opioids for CNCP has produced iatrogenic 142 
dependence and subsequent increases in illicit opioid use, most prominently in the US and 143 
Canada. From the 1990s to around 201110 aggressive promotion, under-regulation, and 144 
overprescribing of pharmaceutical opioids, increased opioid dependence and overdose 145 
deaths substantially11. In the US, interventions were introduced from 201012 to reduce the 146 
supply and extra-medical use of prescribed opioids (e.g., limits on prescribing, prescription 147 
monitoring programs, “pill mill” laws, abuse-deterrent reformulations,). These privileged 148 
reducing supply over reducing demand and increasing access to interventions for people who 149 
had developed problematic opioid use. From the late-2000s onwards10, there were increases 150 
in heroin supply and transitions to heroin use and injection 13. A “third wave” from around 151 
201314 involved an influx of highly potent synthetic opioids such as illicitly manufactured 152 
fentanyl15 (see also Peacock et al14 in this series.) The severity of the opioid problem has 153 
reduced adult life expectancy in the US for two consecutive years, a first since 1964. In British 154 
Columbia in Canada increased use of fentanyl and carfentanyls has reduced life expectancy 155 
despite access to universal health care and considerable harm reduction and treatment 156 
services. There have been similar but far less dramatic shifts in opioid prescribing, illicit opioid 157 
use and overdose in some other countries16. 158 
Prevalence of opioid dependence 159 
The Global Burden of Disease (GBD) study estimated national, regional, and global prevalence 160 
of opioid dependence in 201717 (Figure 2a; see Appendix F for methods and Table F1 for 161 
regional and global opioid dependence estimates). Globally, the age-standardised rate of 162 
opioid dependence was 510 people per 100,000 population (95% uncertainty interval [UI] 163 
430-605; 40.5 million people, 95%UI 34.3-47.9 million). The highest estimated prevalence in 164 
2017 was in the US (age standardised rate of 1,347 per 100,000 (95%UI 1,136-1,609; 4.8 165 
million people, 95%UI 4.1-5.6 million). High rates of opioid dependence were also estimated 166 
in the Middle East and East Asia. 167 




Not everyone who uses opioids extra-medically develops opioid dependence18. A 1991 US 169 
population survey suggested that around one in four people who had used opioids (largely 170 
heroin) experienced dependence at some time prior to interview19, whereas a UK study 171 
adjusting for potential biases estimated that two in three heroin users might become 172 
dependent18. A recent study of US population-based surveys over 15 years suggested that 173 
approximately 30% of people had developed heroin dependence within a year of initiating 174 
use20. A 2011 Iranian population survey found half (49%) of those who had used opioids 175 
(mainly opium) in the past year were opioid dependent21. Dependence can also be context-176 
specific: a seminal 1974 study of US Vietnam war veterans found one in three used heroin in 177 
Vietnam, of whom 59% were dependent during that time, but 98% remitted from 178 
dependence upon returning to the US22. 179 
Estimates of the risk of developing opioid dependence among people prescribed opioids vary 180 
widely. In studies of people prescribed opioids for any pain condition, the median risk 181 
developing dependence has been estimated at 5% (range 0-31%)23; among people with CNCP 182 
prescribed opioids long-term in primary care, estimates vary between 3-26%24. A systematic 183 
review (n=15, mostly US surveys) estimated that 15% of people with past-year extra-medical 184 
opioid use (95%CI 14-17%) might be dependent25 (see appendix E for methods). 185 
The course of opioid dependence 186 
Opioid dependence is best characterised as a chronic, relapsing condition with periods of 187 
active use, abstinence and relapse over years or decades, interspersed with periods of 188 
treatment and/or incarceration26. These periods place individuals at heightened risks of 189 
serious adverse consequences. There is an elevated risk of mortality from overdose,27-29 190 
during treatment initiation or discontinuation, or when tolerance is reduced after a period of 191 
abstinence, treatment cessation, and release from incarceration.  192 
There are few studies on the natural history of pharmaceutical opioid dependence. Some data 193 
from the US suggest elevated risk of transition from extra-medical prescription opioid use to 194 
injectable heroin13,30,31. 195 




Risk factors include genetic, early life, and environment. The social and contextual risks for 197 
extra-medical prescription opioid and illicit opioid use include: drug availability, peer 198 
substance use21,32 ; social norms about substance use33; adverse childhood experiences, 199 
including social disadvantage, family history of drug use34, childhood maltreatment35, 200 
parental conflict36 and problematic parental relationships21,37. Individual risk factors include 201 
being male, externalising disorders in childhood38 and poor educational attainment39. Drug 202 
dependence is partially heritable, but probably a genetic disposition to drug use disorders in 203 
general rather than opioids in particular40. 204 
Panel D - perspectives from people who use opioids 205 
Comorbid substance use and mental health problems 206 
People who use extra-medical opioids typically use multiple substances and often have 207 
comorbid polysubstance use disorders41,42 and mental illnesses43. These relationships are not 208 
necessarily causal but problematic non-opioid use44,45 and depression, anxiety and post-209 
traumatic stress disorders44,45 markedly increase the risk of opioid dependence. Similarly, use 210 
of alcohol, stimulants, benzodiazepines41 and mental health problems46 reduce positive 211 
treatment outcomes for opioid dependence and increasing overdose risk (see later section 212 
on overdose risk). Additional interventions are required when psychiatric comorbidity is 213 
present (see Hall et al47 and Farrell et al48 in this series).  214 
Opioid overdose  215 
Prevalence of fatal opioid overdose  216 
Fatal opioid overdose is a major adverse outcome of prescribed and extra-medical opioid use 217 
that is increasing in the US, the United Kingdom, Canada, Australia and across Europe49. 218 
Globally, GBD 201750 estimated that there were around 109,500 opioid overdose deaths (see 219 
appendix F, Table F1), 43% of which were in the US. As shown in Figure 2b, the highest 220 
estimated fatal opioid overdose rates per 100,000 population were in the Russian Federation, 221 
Eastern European countries and the US.  222 
Not all overdoses are fatal; many more non-fatal overdoses occur than fatal overdoses. A 223 




opioid-related overdoses per 100 person-years (PY), and 0.017 fatal overdoses per 100PY 225 
(7.6:1 ratio).51 By contrast, in a cohort of PWID in Vancouver, Canada, there were 12.0 non-226 
fatal overdoses per 100PY52 and 0.89 fatal overdoses per 100PY – a ratio of 13.5:1.52 227 
Mechanisms of opioid overdose 228 
At higher doses, opioids suppress respiratory rhythm generation and reduce normal 229 
physiological responsiveness of central and peripheral chemoreceptors. As a result, CO2 levels 230 
rise and hypoxia develops,53 breathing rates decrease and eventually stop. More detail on 231 
overdose mechanisms is presented in webappendix G.   232 
Risk factors for fatal opioid-related overdose 233 
Systemic disease comorbidity may increase the risk of fatal opioid overdose e.g. via increased 234 
sensitivity to respiratory depressive effects impaired cardiac function, or impairment of 235 
opioid metabolism because of impaired liver or kidney function. Prolonged hypoxia and loss 236 
of consciousness from multiple overdoses may aggravate systemic disease54,55.  237 
Fatal opioid-related deaths often involve alcohol, benzodiazepines, cocaine and 238 
amphetamines56. Concomitant or polydrug use greatly increases the risks of opioid 239 
overdose57 via synergistic respiratory depressant effects57,58; reverse tolerance to respiratory 240 
depression59,60; and 3) increase risk of relapse in abstinent heroin users61. The use of 241 
gabapentinoids prescribed to treat chronic pain, has increased amongst heroin users 58,62,63. 242 
An increased risk of opioid-related deaths has also been reported for patients prescribed 243 
opioids and gabapentin for the treatment of pain64. 244 
Other health and social harms among people who use opioids 245 
Non-fatal harms among people with opioid dependence  246 
Table 1 summarises evidence for opioid dependence as a risk factor for a range of adverse 247 
outcomes (see webappendix H for methodology). Much of the evidence comes from studies 248 
of people who use heroin, most of whom inject; there are fewer studies among people who 249 




HIV and HCV are a major risk for people who inject drugs (PWID).65 The prevalence of opioid 251 
injecting varies widely geographically and in the main type of opioid used e.g. in South Asian 252 
countries, non-injecting routes of administration have been the most common. Table 1 also 253 
shows that skin and soft tissue infections66, as well as infective endocarditis66, are significant 254 
risks among PWID. Other consequences associated with opioid dependence, include poorer 255 
quality of life67, mental health problems68, increased criminal activity69, and involvement with 256 
the criminal justice system69.  257 
Prolonged heroin use is associated with damage to brain white matter70-72, changes in the 258 
connectivity between cortical and subcortical regions73 and a decrease in grey matter 259 
density74,75. Chronic extra-medical opioid use results in repeated periods of hypoxia during 260 
non-fatal overdoses. The number of non-fatal heroin overdoses predicts neurocognitive 261 
impairment76, though less than other drugs77, head injury, psychiatric comorbidity, and 262 
chronic infection (HCV and HIV)78,79.  263 
Mortality in people with using illicit opioids and prescribed opioids for chronic pain 264 
A systematic review of mortality among people who use opioids (see webappendix I) found 265 
97 eligible cohorts of people using opioids extra-medically 80 and nine cohorts of people 266 
prescribed opioids for chronic non-cancer pain81. The pooled all-cause crude mortality rate 267 
(CMR) in people using extra-medical opioids was 1.7 per 100 person-years (PY; 95%CI 1.5-268 
1.9), nearly 10 times the expected rate for people of that age (standardised mortality ratio 269 
(SMR 9.9; 95% CI 7.5-13.1)). Among people injecting extra-medical opioids, the pooled SMR 270 
was 14.1 (95% CI 10.1-19.7), highlighting a higher risk among injectors. CMRs were highest 271 
for overdose deaths (0.5 per 100PY; 95% CI 0.5-0.6), but AIDS and liver disease were major 272 
causes of mortality (AIDS CMR 0.2 per 100PY; 95% CI 0.1-0.3; liver-related CMR 0.2 per 100PY; 273 
95% CI 0.1-0.3).  274 
In people prescribed opioids for CNCP, the pooled all-cause mortality rate was high (2.4 per 275 
100PY PY; 95% CI 0.9-6.2) owing to the age and poor health of these samples. Overdose 276 
comprised a small proportion of mortality (pooled overdose CMR 0.06 per 100PY; 95% CI 0.01-277 
0.2).    278 




Reducing harms among people who use opioids  280 
Impact of methadone or buprenorphine treatment on outcomes 281 
Varying terms (and their acronyms) are used to describe long-acting opioid agonists or partial 282 
agonists for the treatment of opioid dependence, including ‘methadone maintenance 283 
treatment’ and opioid agonist treatment (OAT). In this paper we use OAT to refer to 284 
methadone or buprenorphine specifically, though all terms have limitations82.  285 
OAT is the most effective treatment for opioid dependence and a WHO Essential Medicine1. 286 
It reduces harms across multiple health outcomes (Table 2 (see webappendix J for methods 287 
and the searches undertaken, and modelling Panel E). Other opioids can be used in the 288 
treatment of opioid dependence; these are summarised in webappendix J in Panel J1). A 289 
range of other services are often provided in addition to OAT, depending upon the setting, 290 
and may include other medical care, mental health services, vocational and other assistance, 291 
and provision of naloxone. 292 
The best evidence for OAT and other interventions is in people using illicit opioids (especially 293 
heroin) and/or PWID. Some evidence suggests that outcomes are also positive for OAT for 294 
people with any pharmaceutical opioid dependence83; evidence is less clear for opium 295 
dependence84. 296 
Table 2 summarises the evidence for the impact of OAT on outcomes in people who are opioid 297 
dependent. It reduces injecting risk behaviour85 and risk of HIV and HCV acquisition86,87, 298 
increases engagement in the HIV88 and HCV cascade of care, reduces criminal activity89 and 299 
reduces all-cause90 and overdose90 mortality. There is weaker evidence that it may reduce o 300 
suicide and accidental injuries91. OAT is highly cost-effective, and cost-saving when costs of 301 
crime are included92.  302 
The protective effect of OAT on mortality is marked in people who experience incarceration, 303 
especially during the highest risk periods in the first weeks post-incarceration, and after 304 
release from prison93,94. This could reduce HIV and HCV transmission, which is also elevated 305 
at these times95. However, OAT is rarely available in these settings. Our modelling (Panel E) 306 




75.0% more deaths over 20 years than only scaling-up in the community, suggesting that 308 
interruptions in OAT during incarceration may limit its population benefits.  309 
Methadone and buprenorphine differ on some outcomes. Retention is higher in patients on 310 
higher doses of methadone (>80mg daily) and lower for buprenorphine and lower methadone 311 
doses (<60mg daily)96. Two studies have found lower risk of mortality during induction onto 312 
methadone vs. buprenorphine, but evidence is unclear on differences at other points in or 313 
out of treatment90,97. Among opioid dependent women who are pregnant, neonatal outcomes 314 
may be superior for women maintained on buprenorphine98. 315 
Higher doses of methadone and buprenorphine increase retention in treatment99. There is 316 
low quality evidence that supervised dosing (i.e. doses provided as directly observed doses 317 
by a pharmacist or other clinical worker) does not improve retention100. There is insufficient 318 
evidence to assess the effectiveness of urine drug screening (UDS) during OAT upon 319 
retention101. Guidance on quality OAT provision developed by WHO is based on evidence 320 
more than a decade old (Panel C summarises WHO guidance; text in bold indicates guidance 321 
based on more recent evidence).  322 
Table 2 – evidence on effectiveness of OAT 323 
Panel C – guidance on OAT provision 324 
Current OAT provision around the globe 325 
A 2017 review102 found very low levels of OAT coverage among PWID (Figure L1). Only 86 of 326 
179 countries with evidence of injecting drug use provided OAT. Coverage was most often 327 
low according to WHO indicators (defined as <20 OAT recipients per 100 PWID per year); only 328 
20 countries (5% of the global PWID population) were implementing high-coverage OAT (>=40 329 
OAT recipients per 100 PWID)102. Retention in OAT can also be poor (Figure L2 in 330 
webappendix L presents data on retention in cohorts in multiple countries). Our 331 
mathematical modelling (see Panel E) demonstrates that scaling-up OAT from low to high 332 
coverage among PWID could avert 2.4-8.1% of all deaths, 9.8-19.3% of overdose deaths and 333 
21.8-34.9% of HIV deaths in people who injected drugs in Kentucky, Tehran and Kiev over the 334 




are projected if OAT retention was improved (to 2 years) and OAT was provided in criminal 336 
justice settings (see Panel E and below).  337 
In a systematic review of OAT in routine clinical practice (search details in Appendix L) sub-338 
optimal dosing of methadone and buprenorphine was common.103 There was greater access 339 
to unsupervised dosing with buprenorphine than methadone103. Limiting access to 340 
unsupervised dosing can mean daily clinic attendance which interferes with employment, 341 
education and family responsibilities, and is a barrier to treatment entry and retention. Use 342 
of urine drug screening in OAT is widespread but there is little evidence that it improves 343 
clinical outcomes 101. Requirements in some countries that OAT client details are reported to 344 
law enforcement agencies are a significant barrier to treatment 103. OAT could be improved 345 
by greater involvement of clients in service design and delivery. Panel D discusses a range of 346 
ways in which OAT access, retention and outcomes could be improved.  347 
There are few data on the impacts of flexible OAT provision on the diversion of OAT 348 
medications. The safety profile of buprenorphine (especially in comparison to illicit opioids 349 
such as fentanyl and heroin) means that these harms are limited. In the UK supervised 350 
community pharmacy provision of methadone reduced methadone-related overdoses 351 
despite an almost 400% increase in patient numbers104.  352 
Modelling impact of OAT scale-up on health outcomes 353 
Panel E presents model projections for three global settings (Kiev (Ukraine), Perry County 354 
(Kentucky, USA) and Tehran (Iran) to evaluate the overall health benefits of OAT among PWID 355 
(model details are presented in webappendix M). Scaling-up OAT to UNAIDS/WHO 356 
recommended coverages of 40% among PWID in the community (current coverage in each 357 
setting is 5-11%) could prevent 2.4-8.6% of all deaths among PWID and people who previously 358 
injected drugs over 2020-2040, with overdose deaths accounting for 22.1-43.7% of all deaths 359 
averted. These mortality reductions would increase up to 1.8-fold if OAT treatment duration 360 
increases to 2 years) and up to 3.2-fold if retention was improved (to 2 years) and access 361 
provided to OAT in prisons and on release. Increasing OAT coverage, improving retention, and 362 
providing OAT in prisons could reduce 57.0% of all overdose deaths among PWID in Kentucky 363 




Our modelling shows that OAT also reduces other causes of mortality and the risk of HIV and 365 
HCV transmission, and rates of incarceration while improving HIV treatment outcomes. The 366 
mortality benefits vary across settings depending upon whether the major causes of death 367 
are due to HIV, as in Kiev and Tehran (where the impact of OAT is greatest), or overdoses, 368 
such as Kentucky. Our findings also highlight the importance of improving OAT retention and 369 
increasing the availability in prisons for maximising reductions in mortality. Importantly, our 370 
analyses focused on the impact of OAT on mortality rather than quality of life which will likely 371 
underestimate the population-level impact of OAT on HIV and HCV morbidity and other 372 
aspects of quality of life67. Nevertheless, our findings still suggest that it is imperative to 373 
expand OAT and improve the quality of OAT provided to PWID globally. 374 
Panel D – improving the access and outcomes of OAT 375 
Panel E – mathematical modelling of the impact of improving OAT coverage and quality 376 
We conducted a review of reviews to examine impacts of various interventions on a wide 377 
range of outcomes (Webappendix J summarises the searches and summarised resulting 378 
reviews located). Table 3 summarises evidence located for effects on injecting risk behaviour, 379 
extra-medical opioid use, HIV and HCV incidence, fatal overdoses, suicides and all-cause 380 
mortality; Table J5 in Webappendix J summarises evidence for impacts on quality of life, skin 381 
and soft tissue infections and accidental injury mortality.  382 
There are several limitations in the evidence. First, the amount and quality of evidence for 383 
many interventions is much lower than for OAT. Second, few interventions had evidence on 384 
their impacts on all the outcomes we considered, and most had a limited impact on a limited 385 
number of outcomes (in contrast to the wider impacts for OAT). 386 
Opioid antagonist treatment 387 
Oral naltrexone is ineffective and has little appeal for many people who are opioid 388 
dependent.105 Extended-release naltrexone (XR-NTX) reduces extra-medical opioid use more 389 
than placebo or treatment referral. The need to withdraw from opioids before initiating XR-390 
NTX limits its use, e.g. 37% of persons in studies of people withdrawing from opioids before 391 
XR-NTX induction did not start treatment.106 Among those who initiate, XR-NTX treatment 392 




have concluded there is very limited and “inconsistent” evidence106 on adherence and 394 
retention in XR-NTX compared to OAT.106 An economic evaluation in a clinical trial comparing 395 
XR-NTX to sublingual buprenorphine-naloxone concluded that buprenorphine was more cost-396 
effective than XR-NTX at 24 and 36 weeks107.  397 
As with OAT27, mortality risk increases after cessation of XR-NTX 108. This suggests that relapse 398 
to opioid use is likely after treatment cessation, and the increased risk of overdose need to 399 
be clearly communicated to people leaving treatment. 400 
Other interventions and policies to reduce opioid-related harms  401 
The provision of clean injecting equipment via needle and syringe programmes (NSP) reduces 402 
injecting risk in PWID109. There is stronger evidence for reduced HIV 110 than HCV incidence87. 403 
Testing for and treating HIV and HCV had positive impacts in people who use drugs111-113. 404 
Many countries are increasing access to naloxone to reverse opioid overdose. The rationale 405 
for this intervention is clear114;it is uncertain what scale of provision is required to reduce 406 
opioid-related overdose mortality in the population. 407 
Despite their low efficacy, psychosocial interventions remain the most commonly delivered 408 
interventions. Evidence suggests benefits of contingency management, cognitive behavioural 409 
therapy and relapse prevention in substance use disorders115. Evidence for their use in opioid 410 
dependence is more mixed115, including whether they improve outcomes over OAT 411 
alone115,116. The more important factors may be quality of clinician training and supervision, 412 
the therapeutic alliance between the clinician and client and integration of clinician and peer-413 
led psychosocial support services.115 414 
Peer-led groups such as Narcotics Anonymous (NA) are one of the most common 415 
interventions globally. These abstinence-oriented programs involve peer support and regular 416 
attendance at group meetings. There is some evidence that of efficacy of Alcoholics 417 
Anonymous in reducing alcohol use for people who are alcohol dependent117, but less for NA. 418 
Medically supervised opioid detoxification using tapered doses of opioids assists people to 419 
complete withdrawal118 but most people relapse to opioid use without additional 420 




by inpatient treatment in a therapeutic community. There was insufficient evidence to assess 422 
whether these are more effective than other interventions because of very high dropout 423 
before completion 119.  424 
Compulsory drug detention centres (CDDCs) are used in some East and Southeast Asian 425 
countries. For example, in Malaysia120, people may be forced to enter a CDDC after a positive 426 
urine drug test, police suspicion of drug use, or at family’s request; detention is for 2 years, 427 
with few effective treatments provided and 18 months’ supervision post-release. A review 428 
concluded that there was no evidence for positive outcomes and some evidence of harm121; 429 
a recent study reported a swifter relapse to opioid use among opioid users leaving CDDCs 430 
than among people leaving methadone treatment120. 431 
 “Abuse-deterrent” formulations (ADF) of pharmaceutical opioids have been introduced to 432 
reduce extra-medical opioid use (e.g. making them more difficult to inject). A systematic 433 
review122 concluded that there was promising but inconclusive” evidence that a tamper-434 
resistant sustained-release formulation of oxycodone was “comparable or better” in reducing 435 
extra-medical use, and other opioid ADF“. The evidence was insufficient to assess its 436 
effectiveness in reducing overdose122. Cost-effectiveness modelling suggested that ADF 437 
opioids costs $231,500 to prevent one new case of extra-medical opioid use, $80,500 to 438 
prevent one abuse-year, and $1.36 billion to prevent an overdose death122. 439 
Evidence for prescription drug monitoring programs (PDMP) and “pain clinic laws” (e.g. 440 
requiring registration , physician ownership , prescribing restrictions, and detailed record-441 
keeping) is mixed123 and insufficient given the low-strength evidence, high risk of bias and 442 
some evidence of increases in heroin overdoses123. Unless it is obligatory for prescribers to 443 
use the system, PDMPs are unlikely to be of benefit. These interventions at best reduce new 444 
cases of opioid dependence but are an insufficient response to opioid use dependence and 445 
related harms124.  446 
A recent systematic review of associations between indicators of criminalisation of drug use 447 
(e.g. exposure to incarceration and street-level policing) and patterns of injecting drug use, 448 
risk behaviours and HIV prevalence125. A formal synthesis was not possible but 86% of studies 449 




prevalence, and reduced engagement with OAT, harm reduction services, and the HIV care 451 
cascade125. Incarceration also increases risks of HCV infection95. People who use drugs see 452 
decriminalisation – as distinct from legalisation - of drug use as critical in reducing drug related 453 
harm and improving quality of life (e.g. Panel B). 454 
Table 3 – evidence for other interventions to reduce opioid-related harm  455 
The future of opioids: What are the anticipated changes, opportunities and 456 
challenges for the coming decade? 457 
Improving access to prescribed opioids as essential medicines requires advocacy and 458 
collaboration of multiple organisations and agencies clear guidance on opioid use for pain and 459 
alternative strategies for managing non-cancer pain. 460 
A comprehensive and evidence-based public health response is required to significantly 461 
reduce opioid dependence and related harms over the coming decades. We need drug policy 462 
to be driven by public health and prevention of health harms; which will require 463 
decriminalisation of drug use and dependence. The global research enterprise should be 464 
supported to develop and evaluate novel interventions to prevent opioid overdose, improve 465 
the quality of treatment for opioid dependence, and identify novel treatments for opioid 466 
dependence and chronic pain.  467 
International attention should be devoted to eliminating the marketing strategies that 468 
contributed to the sharp increase in opioid prescription and harms in North America. If a 469 
public health approach will be essential to address problems arising from illicitly 470 
manufactured fentanyls and other synthetic opioids  471 
We need more research on the effectiveness and cost-effectiveness of novel interventions to 472 
prevent inadvertent exposure to synthetic opioid substances such as drug checking programs 473 
126-128. Developing the technical capacity to detect and measure these drugs will present a 474 
significant challenge in responding to public health issues raised by highly potent synthetic 475 
opioids (see Peacock et al14 in this series). 476 
We need to increase the global coverage and quality of care in f effective interventions such 477 
as OAT and NSP. Continua of care, such as the “cascade” of care for the treatment of HIV 478 




of abstinence or “recovery” should not be the immediate or ultimate goal. Overdose 480 
prevention — and prevention of drug related harm more broadly –are more appropriate 481 
public health objectives. 482 
We need research on how to optimise treatments for opioid dependence by listening to the 483 
views of people who use drugs on what treatments are required at different stages of 484 
dependence, i.e. population-stratified medicine (see Panel B for perspectives from people 485 
who use drugs). We need to know whether novel models of treatment and care provision 486 
(e.g., in primary care, community-based and criminal justice settings) increase access and 487 
improve population-level outcomes. Particularly, we need research on how to improve 488 
retention in treatment and how to design OAT programmes (unsupervised dosing, dedicated 489 
pharmacies etc.) to best prevent overdose. This should include innovative “low threshold” 490 
OAT, including street-based outreach programs, mobile clinics, and home-based induction 491 
that shown promise133. Finally, we need to quantify the impact of interventions other than 492 
OAT on overdose and other health outcomes to design a population-based approach to 493 
treatment choices for people who are opioid dependent. 494 
Opioid agonist and antagonist medications for the treatment of opioid dependence may not 495 
be effective for all patients134. Extended-release formulations of OAT may overcome 496 
challenges posed by the need for daily or near-daily dosing. In the United States, the first 497 
buprenorphine implant for the treatment of opioid dependence was approved by the FDA in 498 
2016135 and depot buprenorphine in 2017. Implementation research is needed to determine 499 
their attractiveness to patients136, improve patient and population outcomes (including 500 
retention), and provide them to scale. We need to identify patient characteristics that predict 501 
successful induction and adherence to XR-NTX and reduce overdose risks during and after 502 
treatment with XR-NTX.106  503 
Finally, the optimal policy and regulatory framework for opioids is one that minimises the 504 
health and social harms arising from extra-medical opioid use and dependence, while 505 
ensuring access to prescribed opioids as essential medications. Further work is needed to 506 




Opioid dependence is the third most important substance use disorder (after tobacco and 508 
alcohol) in terms of contribution to morbidity and premature mortality. The coverage of 509 
interventions to prevention opioid-related health harms is woefully inadequate in most 510 
countries. National and international drug policy, clinical guidance and research is needed to 511 
reduce the scale of opioid-related harm in the world. Drug policies need to move from a focus 512 
on criminal justice to public health. Prevention of harm should be the goal of clinical guidance 513 
and strategies – led by research into how to optimise combinations of pharmacological, 514 
psychological, and harm reduction interventions.  515 
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Panel A: Common terminology used to describe patterns of opioid use  
A range of terms are listed below that are used in the opioid literature137. 
Medical opioid use: use of opioids as prescribed for pain and in the treatment of opioid dependence. 
Extra-medical opioid use:  Encompasses use of pharmaceutical opioids either without a prescription 
(i.e. obtained from outside the formal medical system) or not as directed by a doctor, without 
excluding the possibility that the user may have medically driven reasons for using the opioid. 
Illicit opioid use: use of non-pharmaceutical opioids for extra-medical purposes. 
Diverted opioids: this term can be used in varied ways, some of which are more stigmatising (e.g. use 
in a broad sense, including if a patient does not take medication “as directed”). We propose a more 
restrictive definition,137 which denotes medications diverted from licit sources to unintended 
individuals or the illicit marketplace: selling/trading, sharing, or giving away of prescription 
medications to others (either intentionally or involuntarily). 
Aberrant opioid behaviours: a range of patient practices that fall outside those usually expected in 
treatment of pain or opioid dependence; could have varied reasons including ambivalence about 
treatment, under-treatment, side-effects or emerging opioid-related problems. 
Non-adherent opioid use: use of opioids by the individual to whom they were prescribed, but are not 
taken in accordance with prescription directions or other conditions of treatment not met137. 
Hazardous opioid use: a pattern of opioid use that increases the risks of harmful consequences 
(physical, psychological) for the user or others. It has been defined under “Factors influencing health 
status and encounters with health services” in ICD-11. 
Opioid addiction: a term widely used by the public and health‐care professionals, and in the pain 
literature. It is mainly used as a synonym for opioid dependence but is not a current diagnostic term. 
In common usage, this term invokes a range of social constructs that are value‐laden; many people 
prefer not to use this term. 
Opioid abuse: a historical term used to refer to a drug use disorder (DSM-IV); it is also a more general 
term denoting use that is disapproved of. 
Opioid use disorder: can have varied definitions: in DSM-IV, ICD-10 and ICD-11, denotes either 
abuse/harmful use or dependence; in DSM-5 denotes any use disorder (mild, moderate or severe) and 
may be further classified as in early or sustained remission or in a controlled (e.g., prison, hospital) 
environment. ICD differs from DSM-5 in that DSM-5 criteria are met when any two of 11 criteria are 
endorsed (including criteria previously categorised as DSM-IV abuse); ICD-11 retains the concept of 
dependence. 
Opioid dependence: a maladaptive pattern of opioid use involving a constellation of behaviours 
including physiological signs of dependence, loss of control over use, craving and preoccupation with 
non‐therapeutic use, and continued use despite causing harm (used in ICD-10, ICD-11, DSM-IV). This 
term is not used in DSM-5. 
Harmful opioid use: used by WHO in its ICD classification of use disorder (similar to DSM-IV abuse). 
Illicit opioid dependence: dependence upon illicitly produced opioids, including heroin and illicitly 
manufactured synthetic opioids. 
Pharmaceutical opioid dependence: dependence upon pharmaceutical opioids, which may develop 
under medical supervision138. It may also occur via use of diverted pharmaceutical opioids. 
Abstinence: no longer using the drug that was causing problems; may still be taking agonists as 
prescribed. 
Recovery: definitions vary; however, can refer to a process of change through which people improve 





Figure 1a: Countries with the highest no. standardised defined daily doses (s-DDDs) of opioid analgesics consumed per million people per day, 2016 
 
Figure 1b: Opioid analgesic consumption in highest countries (as at 2016), no. standardised defined daily doses (s-DDDs) of opioid analgesics consumed per 
million people per day, 1990-2016 
 
Source: Data provided by the International Narcotics Control Board. Used 3-year rolling averages. Opioid analgesics includes codeine, dextropropoxyphene, dihydrocodeine, fentanyl, 






























































do not include the full list of narcotic drugs reported in the INCB’s annual reports.It is important to note that there are gaps in reporting of data by member states and there may be differences 





Panel B: Some perspectives from people who use drugs*  
What would you like people to know about people who use drugs? 
He/she could be anyone: their brother, sister, fiancé, professor they like the most, singer or actor they’ve a crush on …people 
who use drugs are simply not bad people. (Male, 39, Nepal) 
We are human we are OK people. We are parents, good and bad like everyone else. We are not demons. We hold down 
responsible jobs, we care, we’re intelligent, we love, we are creative, we have the same faults as others. (Male, 65, France) 
What are the current gaps in the availability, quality and suitability of drug treatment services, health services, and harm 
reduction services for people who use drugs? 
Violation of the rights of PUD, absence of PUD in planning & designing of the program results in to low-quality services and 
involvement. (Male, 39 years, Nepal) 
Total abstinence should not be seen as the only goal, some people might just want to get to a healthier place. (Female, 36, 
Australia) 
What do services need to have in place to make people who use drugs feel welcome and want to access services? 
Sympathy, non-judgmental and welcoming environment (Male, 39 years, Nepal) 
Active involvement of drug using community, gender responsiveness. (Unidentified; Male, 43, South Africa) 
How can people who use drugs and other stakeholders work together to improve the health of people who use drugs? 
Create an environment of trust. (Male, 39, Nepal) 
Share experiences and networking of organisations (Male, 42, Burundi) 
Allow and listen to feedback by people who use drugs…without bias, stereotype…create and maintain avenues for feedback, 
suggestions, comments, compliments within services and agencies. (Female, 53-58, Australia) 
What is the single best thing that could be done to improve the lives of people who use drugs? 
Decriminalisation of drug use. (Male, 49 years, Nepal; Unknown; Female, 43, Australia; Male, 43, Wurundjeri country; Male, 
43, South Africa; Female, 36, Australia; Male, 35, USA; Male, 53, Australia; ; Male, 58, Australia; Male, 54, Australia);  
Legalisation of drug use (Male, 51, UK; Male, 35, USA; Female, 41, Australia; Female, 61, Australia) 
Promote human rights and recognise the humanity of people who use drugs (Male, 42, Burundi; Female, 53-58, Australia; 
Female, 35, India)  





Figure 2: Estimated prevalence of opioid dependence and opioid overdose mortality, Global Burden of 
Disease study 2017 
2a. Estimated age-standardised opioid dependence cases per 100,000 population   
                                   
 









Table 1: Existing evidence for adverse outcomes among people who are opioid dependent  
 People dependent on illicit opioids People prescribed pharmaceutical opioids 
 Effect  Level of 
evidence 
Sources Effect  Level of 
evidence 
Sources 
Non-Fatal outcomes         
Receptive syringe sharing (past year) ↑ 25.5% (16.7, 34.3%) PWID C 65  NA   
HIV incidence ↑ 0.8-10.7 per 100 PY PWID C 86  NA   
HIV prevalence ↑ 17.8% (10.8, 24.8%) PWID C 65  No review level quantitative evidence  68 
HCV incidence ↑ 5.9-42.0 per 100 PY PWID C 87  NA   
HCV prevalence (HCV antibody) ↑ 52.3% (42.4, 62.1%) PWID C 65  No review level quantitative evidence  68 
HCV prevalence (HCV RNA) ↑ 39.2% (31.6, 47.0%) PWID C 140  No review level quantitative evidence  68 
Skin and soft tissue infections…          
 …current ↑ 6.1-32.0% PWID C 66  No review level quantitative evidence  68 
 …past 6-12 months ↑ 6.9-37.3% PWID C 66  No review level quantitative evidence  68 
 …ever ↑ 6.2-68.6% PWID C 66  No review level quantitative evidence  68 
Infective endocarditis (ever) ↑ 0.5-11.8% PWID C 66  No review level quantitative evidence  68 
Quality of life ↓ No review level quantitative evidence C 67  No review level quantitative evidence  68 
Mental health (depression, anxiety) ↑ No review level quantitative evidence   ↑ No review level quantitative evidence  68 
Criminal activity ↑ RaRa 5.84 (1.36, 10.32) SYNTH C 69  NA   
Contact with criminal justice system ↑ RaRa 2.97 (1.43, 4.51) SYNTH C 69  NA   
Non-fatal overdose (ever) ↑ 41.5% (34.6-48.4%)PWID C 141 ↑ No review level quantitative evidence C 141 
Poor neonatal outcomes…         
 …low birth weight ↑ RR 4.61 (2.78-7.65) C 142 ? RR 1.36 (0.83-2.22) METH C 142 
 …neonatal abstinence syndrome ↑ 50-95% C 143 ↑ 47-57% B 144 
 …pre-term birth ↑ TBC  145 ↑ 7-19% B 144 
Fatal outcomes         
Overdose ↑ SMR 58.43 (38.09-89.64) C 80 ↑ CMR 0.63 per 1000PY (0.18-2.23) C 81 
Other accidental injuries ↑ SMR 6.85 (4.41-10.64) C 80  No data C 81 
Suicide ↑ SMR 8.52 (6.00-12.10) C 80  No data C 81 
Cancer ↑ SMR 2.69 (1.84-3.92) C 80  No data C 81 
AIDS-related ↑ SMR 18.50 (8.15-41.99) C 80  No data C 81 
Viral hepatitis ↑ SMR 35.94 (16.06-80.42) C 80  No data C 81 




Note: For details of the search strategies used please see Appendix H and Appendix I. PWID – based on studies of people who inject drugs, not necessarily opioids specifically. SYNTH – authors 
did not pool estimates, but we did for this review. METH – studies examining women on methadone versus controls. RR – relative risk. RaRa – rate ratio. SMR – standardised mortality ratio. 
NA – reviews of pharmaceutical opioid dependent people specifically were not located. ND – reviews indicated that no estimates could be found for this outcome. 
A  Consistent conclusions across meta-analyses, high quality systematic reviews, or multiple randomised controlled trials 
B Evidence from one or two randomised controlled trials only 
C High quality systematic reviews of cohort, case-control or cross-sectional studies 
D  Systematic reviews with inconsistent conclusions from authors or of cross-sectional studies; OR multiple consistent ecological studies  






Table 2: Existing evidence for impacts* of opioid agonist treatment with methadone or buprenorphine 
 Effect Level of 
evidence 
Sources 
OAT vs. no treatment in the community     
Opioid use ↓ RR 0.48 (0.41, 0.55) SYNTH A 85 
Injecting frequency ↓ SMD -0.59 (-0.91, -0.26) SYNTH A  85 
Injecting risk (sharing needles/syringes) ↓ RR 0.53 (0.4, 0.7) SYNTH A  85 
HIV linkage to care and treatment ↑ HR 1.87 (1.50, 2.33) C 88 
HIV treatment adherence ↑ OR 2.14 (1.41, 3.26) C 88 
HIV treatment attrition/discontinuation ↓ OR 0.77 (0.63, 0.95) C 88 
HIV viral suppression ↑ OR 1.45 (1.21, 1.73) C 88 
HIV incidence ↓ RR 0.46 (0.32, 0.67) C 86 
HCV testing ↑ OR 1.73 (1.19, 2.51)  C 146 
HCV linkage to care and treatment ↑ OR 1.40 (0.90, 2.17)  C 146 
HCV treatment sustained virological response  OR 0.75 (0.45, 1.25) C 146 
HCV incidence ↓ RR 0.50 (0.40, 0.63) C 87 
Skin and soft tissue infections  ? NE D 66 
Mental health problems ↓ SMD 0.49 (0.35, 0.63) C 147 
Quality of life (social – WHOQOL-BREF) ↑ SMD 0.29 (0.16, 0.42) C 147 
Criminal activity ↓ SMD -0.57 (-1.00, -0.13)  89 
Contact with the criminal justice system  RR 0.75 (0.46, 1.23) C 148 
Overdose mortality ↓ RaRa 0.25 (0.18, 0.36) SYNTH C 90 
Suicide mortality ↓ RaRa 0.48 (0.39, 0.59) E 91 
Other injury mortality ↓ RaRa 0.40 (0.34, 0.46) E 91 
All-cause mortality ↓ RaRa 0.33 (0.28, 0.39) SYNTH C 90 
OAT vs. no treatment in prison     
Unsanctioned opioid use ↓ NE B 149 
Injecting frequency ↓ NE B 149 
Injecting risk behaviour ↓ NE B 149 
HIV incidence ? NE B 149 
HCV incidence  ? NE B 149 
Prison infractions ↓ NE E 149 
Criminal activity (post-release) ? NE B 149 
Reincarceration ? NE C 149 
OAT engagement (post-release) ↑ NE B 150,151 
HIV treatment adherence (post-release)  NR   
HIV viral suppression (post-release)  NR   
Overdose/suicide/injury mortality (in 
prison) 
↓ aHR 0.13 (0.05, 0.35) E 152 
All-cause mortality (in prison) ↓ aHR 0.26 (0.13, 0.50) E 152 
All-cause mortality (4 weeks post-release) ↓ aHR 0.25 (0.14, 0.45) E 93,94 
Buprenorphine vs. methadone (ref)     
Retention in treatment ↓ RR 0.83 (0.72, 0.95) A 96 
Mortality during induction (4 weeks) ↓ RaRa 0.28 (0.08, 0.95) SYNTH C 90,97 
Mortality remainder in treatment ND RaRa 0.68 (0.44, 1.04) SYNTH C 90,97 
Mortality following cessation (4 weeks) ND RaRa 0.62 (0.16, 2.42) SYNTH C 90,97 
Neonatal outcomes…     
 …Head circumference ↑ RCT WMD 0.91cm (0.14 1.66) B 98 
 …Low birth weight ↓ RCT WMD 324g (32, 617) B 98 
 …Preterm birth ↓ RR 0.40 (0.18, 0.91) B 98 
For details of the search strategies used please see Appendix J.  





SYNTH – we pooled estimates for this review. NR – no quantification located. NE – no quantitative synthesis reported. ND – no 
difference between methadone and buprenorphine detected. RR – relative risk. RaRa – rate ratio. RCT – randomised controlled 
trial. WMD – weighted mean difference. SMD – standardised mean difference. HR – hazard ratio. OR – odds ratio.  
Presence or absence of effect 
 OAT does not appear to have a significant effect upon the outcome 
↑ This outcome may be increased by OAT 
↓This outcome is decreased by OAT 
? Unclear if OAT has an impact on this outcome 
Level of evidence 
A  Consistent conclusions across meta-analyses, high quality systematic reviews, or multiple RCTs 
B Evidence from one or two randomised controlled trials only 
C High quality systematic reviews of cohort, case-control or cross-sectional studies 
D  Systematic reviews with inconsistent conclusions from authors; OR multiple consistent ecological studies 




Panel C – Guidance for opioid agonist treatment (OAT) for the treatment of opioid 
dependence  
The most recent international guidelines for OAT for opioid dependence were released by the World 
Health Organization (WHO) in 2009153, and do not reflect current practice or guidelines elsewhere, 
including several treatment modalities like slow-released morphine and injectable and implantable 
forms of OAT that are now included in standard of practice and national guidelines in many countries. 
The below text combines older recommendations from the WHO guidelines along with some key 
updates (noted in bold text) guided by more recent evidence and featured in national guidelines. It 
will be important for WHO to update the WHO guidelines given the developments in this field in the 
decade since the guidelines were published. 
Due to better retention and greater cost effectiveness, higher-dose methadone might be considered 
the preferred OAT medication153. There are multiple reasons why buprenorphine may be preferred, 
including less rigid supervision and client preference, better safety profile, experience of adverse 
effects or medication interactions with methadone and poor response to methadone153.  
Initial methadone dose depends upon level of tolerance and is 10mg to 30mg (not more than 30mg) 
per day. Doses should be escalated rapidly with monitoring for symptoms of opioid excess to 
promote lower relapse and higher retention. Higher maintenance doses (range 60-120mg per day) 
result in reduced extra-medical opioid use and better retention. Initial buprenorphine dose for clients 
will vary; for those with moderate neuroadaptation it should be 4-8mg, and maintenance doses should 
minimally be at least 8mg (range: 8mg to 24 mg)153. Buprenorphine doses higher than 24mg per day 
are associated with diversion of the medication. 
Doses should be directly supervised early in treatment, especially with methadone. Supervision of 
buprenorphine doses should be variable, and in some cases, home inductions can occur with 
experienced clinicians. Take-away doses (i.e. doses provided to the patient for unsupervised dosing) 
should be provided especially when benefits of reduced frequency of attendance outweigh 
medication diversion risks, and this should be regularly reviewed153.  
The WHO recommendations do not address urine drug screening during OAT. Urine drug testing 
requirements are variable based on settings. When deployed, however, they should be used to 
guide OAT dosing and concomitant psychosocial counselling – not discontinuation of OAT, which 
may result in relapse, overdose and death. 
Clients on methadone can be successfully transferred to buprenorphine, but only when methadone 
doses have been lowered sufficiently, generally below 40mg.  
Pharmacological treatment of opioid dependence should be widely accessible. OAT can be 
successfully provided in multiple settings, including specialty addiction treatment, hospitals, 
primary care and other office-based settings, pharmacies and in criminal justice settings.  
Best practice is considered to involve a range of other interventions as needed by clients, including 
counselling, psychiatric treatment and social supports including assistance with housing, employment, 
education and legal problems. Psychosocially assisted pharmacological treatment should not be 
compulsory because not all patients need it116. Links to psychosocial counselling, HIV, TB and hepatitis 
treatment should be available153. 
Synthesis of available evidence suggests that in many settings, delivery of OAT in routine clinical 
practice may be sub-optimal. Average doses in some countries appear to be below the minimum 






Table 3: Current evidence for effects of interventions to address key outcomes and behaviours among people who use opioids extra-medically 
 Injecting risk behaviours Extra-medical opioid use HIV incidence HCV incidence Overdose Overall mortality 
Intervention 
Effect Size of 
effect 
Level Sources Effect Size of 
effect 
Level Sources Effect Size of effect Level Sources Effect Size of 
effect 




Effect Size of 
effect 
Level Sources 
Provision of sterile 
injecting equipment 
↓ aOR 0.52 
(0.32, 0.83) 
APWID 109 - - - - ↓ OR/HR/RR 0.42 
(0.22, 0.81) 
CPWID 110 ↓? RR 0.77 
(0.38, 1.54) 
C 87 - - - - - - - - 
Condom provision 
- - - - - - - - ↓ RR 0.29, 
(0.20, 0.43) 
AGEN 154 ? - C 155 - - - - - - - - 
Naloxone - - - - - - - - - - - - - - - - ↓ - D 156 - - - - 
Drug consumption rooms 
↓ RR 0.31 
(0.17, 0.55) 
CPWID 157 - - - - ? - D 158 ? - D 158 ↓ - D 159 - - - - 
Peer-based self-help 
groups 
- - - - ↓? - BALC 117 - - - - - - - - - - - - - - - - 
Psychosocial interventions 
↓ SMD -0.43 
(-0.69, -0.18) 
A 160 ↓ WMES -0.18 
(-0.30, -0.06) 
A 161 ? - D 158 ? - D 158 - - - - - - - - 
Opioid detoxification alone                         
Oral opioid antagonists 
 NE A 162  RR 1.39 
(0.61, 3.17) 
A 105 - - - - - - - - - - - - - - - - 
Extended-release opioid 
antagonists 
↓ NE A 106 ↓ NE A 106 - - - - - - - - ↓? - A 106 ? - A 106 
Opioid agonist treatment 
↓ RR 0.53 
(0.4, 0.7) 
SYNTH 
A 85 ↓ RR 0.48 
(0.41, 0.55)  
SYNTH 
A 85 ↓ RR 0.46  
(0.32, 0.67) 
C 86 ↓ RR 0.50 
(0.40, 0.63) 
C 87 ↓ RaRa 0.25 
(0.18, 0.36) 
SYNTH 




Residential rehabilitation ↓ NE C 163 ↓ NE C 163 - - - - - - - - - - - - - - - - 
HIV testing + informing of 
serostatus 
↓ NE DPWID 113 - - - - - - - - - - - - - - - - - - - - 
HCV testing + informing of 
serostatus 
 aOR 0.97 
(0.94, 1.00) 
CPWID 164 - - - - - - - - - - - - - - - - - - - - 
HIV treatment 
 aOR 0.78 
(0.42-1.45) 
D 165 - - - - ↓ - D 112 - - - - - - - - - - - - 
HCV treatment ↓ NE DPWID 111 ↓ NE DPWID 111 - - - - - - - - - - - - - - - - 
STI treatment - - - - - - - - ↓  AGEN 166 - - - - - - - - - - - - 
Suicide prevention 
strategies 
- - - - - - - - - - - - - - - - - - - - - - - - 
Opioid prescribing limits - - - - ↓? NE DGEN 167 - - - - - - - - ↓? - DGEN 167 - - - - 
Abuse-deterrent opioid 
formulations 
↓ NE D 122 ? NE D 122 - - - - - - - - ? - DGEN 122 ? - D 122 
Prescription opioid 
monitoring programs 




↑ NE C* 121 - - - - - - - - - - - - - - - - - - - - 
Criminalisation of drug 
use 
↑ NE CPWID 125     ↑ NE CPWID 125     - - - - - - - - 
U 
Notes on codes used in this table 
Presence or absence of effect 
 This intervention does not appear to have a significant effect upon the outcome 
↑ This outcome may be increased by the intervention 
↓This outcome is decreased by the intervention 
- No evidence could be located of the impact of this intervention upon the outcome 
? unclear evidence on impact of this intervention on the outcome 
Level of evidence 
A Consistent conclusions across meta-analyses, high quality systematic reviews, or multiple randomised controlled trials 
B Evidence from one or two randomised controlled trials only 
C High quality systematic reviews of cohort, case-control or cross-sectional studies 
D  Systematic reviews with inconsistent conclusions from authors or cross-sectional; OR multiple consistent ecological studies  
E Cross-sectional association, case series suggesting outcome, single cohort study 
GEN Evidence drawn from people who may not specifically use any drugs (including opioids) 
PWID People who inject drugs that may not include opioids 
ALC Note that this evidence pertains to people attending alcoholics anonymous 




Panel E: Mathematical modelling of the impact of improving coverage and quality of OAT on multiple 
health outcomes across three global settings 
We performed modelling to evaluate the overall health benefits of OAT amongst PWID in 3 global settings: Kiev 
(Ukraine), Appalachian Kentucky (USA) and Tehran (Iran) (for details see Webappendix M). The single-sex, dynamic 
model, calibrated within a Bayesian framework to data from each setting, captures effects of OAT on all-cause 
mortality, injury, overdose and suicide deaths, HIV and HCV transmission, HIV treatment outcomes, and incarceration 
(linked to greater risk of HIV and HCV transmission among PWID95). The contrasting settings were chosen because of 
differences in HIV and HCV epidemics, overdose mortality and intervention coverage, their geographical spread and 
data availability (Figure E1). Model analyses evaluated the percentage of deaths averted and life years gained (LYG) 
compared to a scenario with no OAT, of: current OAT coverage (Status Quo Scenario); scaling-up OAT coverage to 
40% in the community, as recommended by WHO/UNAIDS (Scale-up Scenario A); additionally, increasing the average 
duration of OAT to 2 years (Scale-up Scenario B); additionally, scaling-up OAT in prison (Scale-up Scenario C).  
Current levels of OAT are projected to have negligible impact on mortality in Kentucky and Kiev but substantial impact 
in Tehran where OAT coverage is greatest and provided in prisons (Figure E2; Table M8 in Webappendix M shows 
these estimates and their 95%CrI); averting  0.3% (95%CrI: 0.1-0.6), 0.8% (95%CrI: 0.5-1.4) and 6.5% (95%CrI: 2.5-12.1) 
of deaths and gaining18.5 (95%CrI: 9.1-32.8), 119.6 (95%CrI: 61.8-206.1) and 1062.6 (95%CrI: 385.0-2003.3) life-years 
per 1,000 PWID over the next 20 years in Kentucky, Kiev, and Tehran, respectively. Scaling-up OAT in the community 
(Scale-up Scenario A) could avert between 2.4% (Kentucky; 95%CrI: 1.2-4.5) and 12.5% (Tehran; 95%CrI: 6.0-18.0) of 
all deaths and 12.7% (Tehran; 6.6-18.5) and 19.3% (Kiev; 95%CrI: 16.3-21.6) of overdose deaths, and gain between 
161.3 (Kentucky; 95%CrI: 84.6-258.9) and 1878.9 (Tehran; 95%CrI: 859.9-3262.8) life-years per 1,000 PWID over the 
next 20 years. Extending the average duration of OAT (Scale-up Scenario B) would have additional benefits, particularly 
on reducing overdose deaths; with between 4.4% (Kentucky; 95%CrI: 2.4-8.5) and 16.7% (Tehran; 95%CrI: 9.1-22.4) of 
all deaths averted and 1.6-2.3 times more overdose deaths averted compared to scaling-up OAT without improving 
retention. Model projections also show that interruptions in OAT due to incarceration may limit the impact of OAT; in 
Kentucky, for example, 7.7% (4.4 - 13.3) of deaths and 57.0% (48.1 - 62.9)of overdose deaths could be averted if OAT 
is also provided in prisons with retention upon release (Scale-up Scenario C). However, limited impact on HCV deaths 
is achieved due to many of the HCV deaths occurring among those with existing infections prior to OAT scale-up.  
The impact of scaling-up OAT on all-cause mortality varies substantially between the three settings primarily because 
of differences in how the varied harms associated with drug use contribute to mortality among PWID. This impact is 
greatest in Kiev and Tehran where the primary cause of death associated with drug use is HIV (27.8% (95%CrI: 20.1-
36.5) and 21.3% (95%CrI: 6.5-42.7) of all deaths in Kiev and Tehran, respectively). Lower impact of scaling-up OAT is 
achieved in Kentucky, where overdose is the primary cause of death associated with drug use and only accounts for 
8.1% (95%CrI: 4.4-15.7) of all deaths. This is further demonstrated by how each effect of OAT contributed to the overall 
impact of scaling-up OAT. For Scale-up Scenario C, the effect of OAT on HIV transmission was the most important 
effect in reducing mortality in Kiev and Tehran accounting for 41.3% (95%CrI: 28.6-60.1) and 69.1% (95%CrI: 31.7-92.9) 
of deaths averted, respectively, whilst in Kentucky, the most important effect was the effect of OAT on overdose, 
accounting for 55.0% (95%CrI: 32.7-75.8) of deaths averted.  





Figure E2: Causes of death among PWID and ex-PWID; 2020-2040.  
Figure shows the median percentage of deaths due to overdose, suicide, injury, HIV, HCV or other causes under the following strategies: if there 
were no OAT from 2020; if OAT was scaled-up to 40% coverage among PWID in the community; if OAT was scaled-up to 40% coverage among 
PWID in the community and the average duration of OAT is increased to 2-years; if OAT was scaled-up to 40% coverage among PWID in the 
community, incarcerated PWID enrol onto OAT at the same rate and the average duration of OAT is increased to 2-years. Deaths from other 
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